A review of potential neuropathological changes associated with ketamine

References

• Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9(1). DOI:10.1186/1741-7015-9-90.
   PubMedGoogle Scholar
• Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27(8):959–985.
   PubMed Web of Science ®Google Scholar
• Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry. 1997;54(11):989–991.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34(1):119–138.
   PubMed Web of Science ®Google Scholar
• Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369–388.
   PubMed Web of Science ®Google Scholar
• Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019;19(1):247.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Filteau M-J, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7.
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Carvalho IP, Lui LMW, et al. The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis. J Affect Disord. 2020;276:576–584.
   PubMed Web of Science ®Google Scholar
• Rodrigues NB, McIntyre RS, Lipsitz O, et al. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: results from the Canadian rapid treatment center of excellence. J Affect Disord. 2020;276:570–575.
   PubMed Web of Science ®Google Scholar
• Sałat K, Siwek A, Starowicz G, et al. Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: role of activity at NMDA receptor. Neuropharmacology. 2015;99:301–307.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Schulz D, Aksoy A, et al. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav. 2002;71(1–2):341–344.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–864.
   PubMed Web of Science ®Google Scholar
• RS M, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30(6):515–527.
   PubMed Web of Science ®Google Scholar
• Zhang MWB, Ho RCM. Controversies of the effect of ketamine on cognition. Front Psychiatry. 2016;7(1). DOI:10.3389/fpsyt.2016.00047
   Google Scholar
• McIntyre RS, Rosenblat JD, Rodrigues NB, et al.The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: results from the Canadian rapid treatment center of excellence (CRTCE). Psychiatry Res. 2021;302:3.
   PubMed Web of Science ®Google Scholar
• H G, Gill B, Rodrigues NB, et al. The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research. Neurosci Biobehav Rev. 2021;120:78–85.
   PubMed Web of Science ®Google Scholar
• Allen HL, Iversen LL, Olney JW, et al. Phencycidine, dizocilpine, and cerebrocortical neurons. Science. 1990;247(221):221.
   PubMedGoogle Scholar
• Ellison G, Switzer RC. Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport. 1993;5(1):17–20.
   PubMed Web of Science ®Google Scholar
• Fix AS, Horn JW, Wightman KA, et al. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol. 1993;123(2):204–215.
   PubMed Web of Science ®Google Scholar
• Fix AS, Wozniak DF, Truex LL, et al. Quantitative analysis of factors influencing neuronal necrosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex. Brain Res. 696, 194–204 (1995).
   PubMed Web of Science ®Google Scholar
• Jevtović-Todorović V, Todorovć SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4(4):460–463.
   PubMed Web of Science ®Google Scholar
• Wozniak DF, Dikranian K, Ishimaru MJ, et al. Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: potential relevance to Alzheimer’s disease. Neurobiol Dis. 1998;5(5):305–322.
   PubMed Web of Science ®Google Scholar
• Ferguson BR, Gao WJ. Pv interneurons: critical regulators of E/I balance for prefrontal cortex-dependent behavior and psychiatric disorders. Front Neural Circuits. 2018;12. DOI:10.3389/fncir.2018.00037
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Kubota Y. GABAergic cell subtypes and their synaptic connections in rat frontal cortex. Cereb Cortex. 1997;7(6):476–486.
   PubMed Web of Science ®Google Scholar
• Murray AJ, Woloszynowska-Fraser MU, Ansel-Bollepalli L, et al. Parvalbumin-positive interneurons of the prefrontal cortex support working memory and cognitive flexibility. Sci Rep. 2015;5(1):16778.
   PubMedGoogle Scholar
• Behrens MM, Ali SS, Dao DN, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 2007;318(80):1645–1647.
   PubMedGoogle Scholar
• Morrow BA, Elsworth JD, Roth RH. Repeated phencyclidine in monkeys results in loss of parvalbumin-containing axo-axonic projections in the prefrontal cortex. Psychopharmacology (Berl). 2007;192(2):283–290.
   PubMed Web of Science ®Google Scholar
• Behrens MM, Ali SS, Dugan LL. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci. 2008;28(51):13957–13966.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull. 2008;34(5):944–961.
   PubMed Web of Science ®Google Scholar
• Gerhard DM, Pothula S, Liu R, et al. GABA interneurons are the cellular trigger for ketamine’s rapid antidepressant actions. J Clin Invest. 2020;130(3):1336–1349.
   PubMed Web of Science ®Google Scholar
• Donegan JJ, Lodge DJ. Hippocampal perineuronal nets are required for the sustained antidepressant effect of ketamine. Int J Neuropsychopharmacol. 2017;20(4):354–358.
   PubMed Web of Science ®Google Scholar
• Gerhard DM, Pothula S, Liu R-J, et al. GABA interneurons are the cellular trigger for ketamine’s rapid antidepressant actions. J Clin Invest. 2020;130(3):1336–1349.
   PubMed Web of Science ®Google Scholar
• Eidenmuller J, Fath T, Hellwig A, et al. Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins. Biochemistry. 2000;39(43):13166–13175.
   PubMed Web of Science ®Google Scholar
• Jin HY, Hu Z, Dong M, et al. Ketamine induces tau hyperphosphorylation at serine 404 in the hippocampus of neonatal rats. Neural Regen Res. 2013;8(17):1590–1596.
   PubMed Web of Science ®Google Scholar
• Wen G, Yao H, Li Y, et al. Regulation of tau protein on the antidepressant effects of ketamine in the chronic unpredictable mild stress model. Front Psychiatry. 2019;10. DOI:10.3389/fpsyt.2019.00287.
   PubMedGoogle Scholar
• Hector A, McAnulty C, Piche-Lemieux ME, et al. Tau hyperphosphorylation induced by the anesthetic agent ketamine/xylazine involved the calmodulin‐dependent protein kinase II. FASEB J. 2020;34(2):2968–2977.
   PubMed Web of Science ®Google Scholar
• Olney JW, Labruyere J, Wang G, et al. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254(80):1515–1518.
   PubMedGoogle Scholar
• Coyle JT, Schwarcz R. The discovery and characterization of targeted perikaryal-specific brain lesions with excitotoxins. Front Neurosci. 2020;14:927.
   PubMed Web of Science ®Google Scholar
• Geraci F, Turturici G, Sconzo G. Hsp70 and its molecular role in nervous system diseases. Biochem Res Int. 2011;2011. DOI:10.1155/2011/618127
   PubMedGoogle Scholar
• Li PA, Liu GJ, He QP, et al. Production of hydroxyl free radical by brain tissues in hyperglycemic rats subjected to transient forebrain ischemia. Free Radic Biol Med. 1999;27(9–10):1033–1040.
   PubMed Web of Science ®Google Scholar
• Ma D, Wilhelm S, Maze M. Neuroprotective and neurotoxic properties of the ‘inert’ gas, xenon. Br J Anaesth. 2002;89(5):739–746.
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Farber NB, Olney JW. NMDA receptor function, memory, and brain aging. Dialog Clin Neurosci. 2000;2(3):219–232.
   PubMedGoogle Scholar
• Olney JW, Farber NB, Wozniak DF, et al. Environmental agents that have the potential to trigger massive apoptotic neurodegeneration in the developing brain. Environ Health Perspect. 2000;108:383–388.
   PubMed Web of Science ®Google Scholar
• Switzer RC, Lowry-Franssen C, Benkovic SA. Recommended neuroanatomical sampling practices for comprehensive brain evaluation in nonclinical safety studies. Toxicol Pathol. 2011;39(1):73–84.
   PubMed Web of Science ®Google Scholar
• Leech R, Sharp DJ. The role of the posterior cingulate cortex in cognition and disease. Brain;137 12–32 (2014).
   PubMed Web of Science ®Google Scholar
• Vogt BA, Laureys S. Posterior cingulate, precuneal and retrosplenial cortices: cytology and components of the neural network correlates of consciousness. Prog Brain Res;150 205–217 (2005).
   PubMed Web of Science ®Google Scholar
• Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244(80):1360–1362.
   PubMedGoogle Scholar
• Ng LHL, Huang Y, Han L, et al. Ketamine and selective activation of parvalbumin interneurons inhibit stress-induced dendritic spine elimination. Transl Psychiatry. 2018;8(1). DOI:10.1038/s41398-018-0321-5.
   PubMedGoogle Scholar
• Yang C, Shirayama Y, Zhang JC, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5(9):e632–e632.
   PubMed Web of Science ®Google Scholar
• Zhou ZQ, Zhang G, Li X, et al. Loss of phenotype of parvalbumin interneurons in rat prefrontal cortex is involved in antidepressant- and propsychotic-like behaviors following acute and repeated ketamine administration. Mol Neurobiol. 2015;51(2):808–819.
   PubMed Web of Science ®Google Scholar
• Honeycutt JA, Chrobak JJ. Parvalbumin loss following chronic sub-anesthetic NMDA antagonist treatment is age-dependent in the hippocampus: implications for modeling NMDA hypofunction. Neuroscience. 2018;393:73–82.
   PubMedGoogle Scholar
• Zhang Y, Behrens MM, Lisman JE. Prolonged exposure to NMDAR antagonist suppresses inhibitory synaptic transmission in prefrontal cortex. J Neurophysiol. 2008;100(2):959–965.
   PubMedGoogle Scholar
• Jeevakumar V, Kroener S. Ketamine administration during the second postnatal week alters synaptic properties of fast-spiking interneurons in the medial prefrontal cortex of adult mice. Cereb Cortex. 2016;26(3):1117–1129.
   PubMed Web of Science ®Google Scholar
• Keilhoff G, Becker A, Grecksch G, et al. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience. 2004;126(3):591–598.
   PubMed Web of Science ®Google Scholar
• Koh MT, Shao Y, Sherwood A, et al. Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia. Schizophr Res. 2016;171(1–3):187–194.
   PubMed Web of Science ®Google Scholar
• Kokkinou M, Irvine EE, Bonsall DR, et al. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. Mol Psychiatry. 2020;26(6):2562–2576.
   PubMed Web of Science ®Google Scholar
• Matuszko G, Curreli S, Kaushik R, et al. Extracellular matrix alterations in the ketamine model of schizophrenia. Neuroscience. 2017;350:13–22.
   PubMedGoogle Scholar
• Pérez MÁ, Morales C, Santander O, et al. Ketamine-treatment during late adolescence impairs inhibitory synaptic transmission in the prefrontal cortex and working memory in adult rats. Front Cell Neurosci. 2019;13. DOI:10.3389/fncel.2019.00372.
   PubMed Web of Science ®Google Scholar
• Sabbagh JJ, Murtishaw AS, Bolton MM, et al. Chronic ketamine produces altered distribution of parvalbumin-positive cells in the hippocampus of adult rats. Neurosci Lett. 2013;550:69–74.
   PubMed Web of Science ®Google Scholar
• Schobel SA, Chaudhury N, Khan U, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 2013;78:81–93.
   PubMed Web of Science ®Google Scholar
• Li Y, Ding R, Ren X, et al. Long-term ketamine administration causes Tau protein phosphorylation and Tau protein-dependent AMPA receptor reduction in the hippocampus of mice. Toxicol Lett. 2019;315:107–115.
   PubMed Web of Science ®Google Scholar
• Yeung LY, Wai MSM, Fan M, et al. Hyperphosphorylated tau in the brains of mice and monkeys with long-term administration of ketamine. Toxicol Lett. 2010;193(2):189–193.
   PubMed Web of Science ®Google Scholar
• Carlson PJ, Diazgranados N, Nugent AC, et al. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry. 2013;73(12):1213–1221.
   PubMed Web of Science ®Google Scholar
• Fox GE, Li M, Zhao F, et al. Distinct retrosplenial cortex cell populations and their spike dynamics during ketamine-induced unconscious state. PLoS One. 2017;12(10):e0187198.
   PubMed Web of Science ®Google Scholar
• Jevtovic-Todorovic V, Benshoff N, Olney JW. Ketamine potentiates cerebrocortical damage induced by the common anaesthetic agent nitrous oxide in adult rats. BrJ Pharmacol. 2000;130(7):1692–1698.
   PubMedGoogle Scholar
• Jevtovic-Todorovic V, Carter LB. The anesthetics nitrous oxide and ketamine are more neurotoxic to old than to young rat brain. Neurobiol Aging. 2005;26(6):947–956.
   PubMed Web of Science ®Google Scholar
• Nagata A, Nakao SI, Nishizawa N, et al. Xenon inhibits but N2O enhances ketamine-induced c-Fos expression in the rat posterior cingulate and retrosplenial cortices. Anesth. Analg. 92, 362–368 (2001).
   PubMed Web of Science ®Google Scholar
• Nakao S, Miyamoto E, Masuzawa M, et al. Ketamine-induced c-Fos expression in the mouse posterior cingulate and retrosplenial cortices is mediated not only via NMDA receptors but also via sigma receptors. Brain Res. 926, 191–196 (2002).
   PubMed Web of Science ®Google Scholar
• Tian Z, Dong C, Fujita A, et al. Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine. Pharmacol Biochem Behav. 2018;172:17–21.
   PubMed Web of Science ®Google Scholar
• Zou X, Patterson TA, Divine RL, et al. Prolonged exposure to ketamine increases neurodegeneration in the developing monkey brain. Int J Dev Neurosci. 2009;27(7):727–731.
   PubMed Web of Science ®Google Scholar
• Zuo DY Wu YL, Yao WX, et al. Effect of MK-801 and ketamine on hydroxyl radical generation in the posterior cingulate and retrosplenial cortex of free-moving mice, as determined by in vivo microdialysis. Pharmacol Biochem Behav. 2007;86:1–7.
   PubMed Web of Science ®Google Scholar
• Wang C, Zheng D, Xu J, et al. Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Front Neuroanat. 2013;7. DOI:10.3389/fnana.2013.00023.
   Web of Science ®Google Scholar
• Lodge DJ, Behrens MM, Grace AA. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci. 2009;29(8):2344–2354.
   PubMed Web of Science ®Google Scholar
• Morgan CJA, Riccelli M, Maitland CH, et al. Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users. Drug Alcohol Depend. 2004;75(3):301–308.
   PubMed Web of Science ®Google Scholar
• Giesers NK, Wirths O. Loss of hippocampal calretinin and parvalbumin interneurons in the 5XFAD mouse model of Alzheimer’s disease. ASN Neuro. 2020;12:175909142092535.
   Web of Science ®Google Scholar
• Verret L, Mann E, Hang G, et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012;149(3):708–721.
   PubMed Web of Science ®Google Scholar
• Herrmann CS, Demiralp T. Human EEG gamma oscillations in neuropsychiatric disorders. Clin Neurophysiol. 2005;116(12):2719–2733.
   PubMed Web of Science ®Google Scholar
• Murphy MP, Levine H, Lovell MA. Alzheimer’s disease and the amyloid-β peptide. J Alzheimers Dis. 2010;19(1):311–323.
   PubMed Web of Science ®Google Scholar
• Rolls ET. The cingulate cortex and limbic systems for action, emotion, and memory. Brain Structure and Function. In: Handbook of clinical neurology. Vol. 166. Elsevier B.V.; 2019. p. 23–37.
   Google Scholar
• Leech R, Smallwood J, Vogt BA. The posterior cingulate cortex: insights from structure and function. in Handbook of clinical neurology. 166 73–85 ( Elsevier B.V., 2019).
   PubMedGoogle Scholar
• Väisänen J, Ihalainen J, Tanila H, et al. Effects of NMDA-receptor antagonist treatment on c-fos expression in rat brain areas implicated in schizophrenia. Cell Mol Neurobiol. 2004;24(6):769–780.
   PubMedGoogle Scholar
• Dragunow M, Faull R. The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Methods. 1989;29(3):261–265.
   PubMedGoogle Scholar
• Hustveit O, Maurset A, Øye I. Interaction of the chiral forms of Ketamine with opioid, phencyclidine, σ and muscarinic receptors. Pharmacol Toxicol. 1995;77(6):355–359.
   PubMedGoogle Scholar
• Taylor KS, Seminowicz DA, Davis KD. Two systems of resting state connectivity between the insula and cingulate cortex. Hum Brain Mapp. 2009;30(9):2731–2745.
   PubMed Web of Science ®Google Scholar
• Li J, Xu C, Cao X, et al. Abnormal activation of the occipital lobes during emotion picture processing in major depressive disorder patients. Neural Regen Res. 2013;8(18):1693.
   PubMed Web of Science ®Google Scholar
• Mao N, Che K, Chu T, et al. Aberrant resting-state brain function in adolescent depression. Front Psychol. 2020;11:1784.
   PubMedGoogle Scholar
• Müller VI, Cieslik EC, Laird AR, et al. Dysregulated left inferior parietal activity in schizophrenia and depression: functional connectivity and characterization. Front Hum Neurosci. 2013; 268.
   PubMed Web of Science ®Google Scholar
• Sliz D, Hayley S. Major depressive disorder and alterations in insular cortical activity: a review of current functional magnetic imaging research. Front Hum Neurosci. 2012;6. DOI:10.3389/fnhum.2012.00323
   PubMed Web of Science ®Google Scholar
• Lee SW, Choi J, Lee J-S, et al. Altered function of ventrolateral prefrontal cortex in adolescents with peer verbal abuse history. Psychiatry Investig. 2017;14(4):441–451.
   PubMed Web of Science ®Google Scholar
• Grimm S, Beck J, Schuepbach D, et al. Imbalance between left and right dorsolateral prefrontal cortex in major depression is linked to negative emotional judgment: an fMRI study in severe major depressive disorder. Biol Psychiatry. 2008;63(4):369–376.
   PubMed Web of Science ®Google Scholar
• Buckner RL. The cerebellum and cognitive function: 25 years of insight from anatomy and neuroimaging. Neuron. 2013;80(3):807–815.
   PubMed Web of Science ®Google Scholar
• Burton AC, Nakamura K, Roesch MR. From ventral-medial to dorsal-lateral striatum: neural correlates of reward-guided decision-making. Neurobiol Learn Mem. 2015;117:51–59.
   PubMed Web of Science ®Google Scholar
• Crespo-Facorro B, Kim -J-J, Andreasen NC, et al. Human frontal cortex: an MRI-based parcellation method. Neuroimage. 1999;10(5):500–519.
   PubMed Web of Science ®Google Scholar
• Dieterich M, Brandt T. The parietal lobe and the vestibular system.In Vallar G, Coslett HB, editors. Handbook of clinical Neurology. Vol. 151. : Elsevier B.V.; 2018. p. 119–140.
   Google Scholar
• Loprinzi PD. The effects of physical exercise on parahippocampal function. Physiol Int. 2019;106(2):114–127.
   PubMed Web of Science ®Google Scholar
• Ngeles Fernández-Gil M, Palacios-Bote R, Leo-Barahona M, et al. Anatomy of the brainstem: a gaze into the stem of life. Semin Ultrasound, CT MRI. 2010;31(3):196–219.
   PubMed Web of Science ®Google Scholar
• Van Ackeren MJ, Barbero FM, Mattioni S, et al. Neuronal populations in the occipital cortex of the blind synchronize to the temporal dynamics of speech. Elife. 2018;7. DOI: 10.7554/eLife.31640
   PubMed Web of Science ®Google Scholar
• McEvoy LK, Fennema-Notestine C, Roddey JC, et al. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology. 2009;251(1):195–205.
   PubMed Web of Science ®Google Scholar
• Rabinovici GD, Seeley WW, Kim EJ, et al., Distinct MRI atrophy patterns in autopsy-proven Alzheimer’s disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 22(6): 474–488. 2008.
   Google Scholar
• Zwick LS, Patrick DJ, Knupp LC, et al. Ketamine/Xylazine anesthesia–related corneal lesions in rats with surgically implanted venous catheters utilized in nonclinical intravenous studies. Toxicol Pathol. 2020. DOI:10.1177/0192623320960705
   PubMed Web of Science ®Google Scholar
• Réus GZ, Titus SE, Abelaira HM, et al. Neurochemical correlation between major depressive disorder and neurodegenerative diseases. Life Sci. 2016;158:121–129.
   PubMed Web of Science ®Google Scholar